Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBT (2023 - 2025)

Historic EBT for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$43.7 million.

  • CG Oncology's EBT fell 11422.34% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 10798.61%. This contributed to the annual value of -$88.0 million for FY2024, which is 8136.16% down from last year.
  • According to the latest figures from Q3 2025, CG Oncology's EBT is -$43.7 million, which was down 11422.34% from -$41.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's EBT registered a high of -$8.7 million during Q1 2023, and its lowest value of -$43.7 million during Q3 2025.
  • For the 3-year period, CG Oncology's EBT averaged around -$23.3 million, with its median value being -$18.9 million (2024).
  • As far as peak fluctuations go, CG Oncology's EBT tumbled by 6365.21% in 2024, and later plummeted by 11904.81% in 2025.
  • Over the past 3 years, CG Oncology's EBT (Quarter) stood at -$16.6 million in 2023, then tumbled by 92.16% to -$31.8 million in 2024, then tumbled by 37.43% to -$43.7 million in 2025.
  • Its EBT stands at -$43.7 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$34.5 million for Q1 2025.